Boston Scientific Unveils Positive Data for Cardiac Therapies
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy BSX?
Source: Newsfilter
- Clinical Trial Results: The FARAPULSE™ Pulsed Field Ablation platform demonstrated a primary effectiveness rate of 56.0% in the AVANT GUARD trial, significantly surpassing the 30.1% rate of anti-arrhythmic drugs, indicating its potential in treating patients with persistent atrial fibrillation and possibly enhancing the company's leadership in the cardiac treatment market.
- Safety Metrics Achieved: The trial met its primary safety endpoint with a major adverse event rate of only 5.1% at 12 months, providing robust safety support for the clinical application of the FARAPULSE™ technology and boosting physician confidence in its use.
- Device Efficacy: The ELEVATE-PF feasibility trial showed that the FARAFLEX™ PFA catheter increased pulmonary vein isolation durability from 80.4% to 96.4%, demonstrating its effectiveness in treating complex arrhythmias and potentially laying the groundwork for future market adoption.
- Success of Combined Therapies: The ALIGN-AF study indicated a 100% procedural success rate for the combined use of the FARAWAVE PFA catheter and the WATCHMAN FLX™ LAAC device, suggesting that their joint application is both safe and effective in clinical settings, which may drive the expansion of the company's product offerings in cardiac care.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise
22 Analyst Rating
22 Buy
0 Hold
0 Sell
Strong Buy
Current: 65.690
Low
94.00
Averages
108.14
High
132.00
Current: 65.690
Low
94.00
Averages
108.14
High
132.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Boston Scientific Releases New Data on Cardiac Therapies
- Clinical Trial Results: The FARAPULSE™ PFA platform demonstrated a primary effectiveness rate of 56.0% in the AVANT GUARD trial, significantly surpassing the 30.1% rate of anti-arrhythmic drugs, indicating its potential in treating patients with persistent atrial fibrillation and potentially enhancing the company's leadership in the cardiac treatment market.
- Safety Validation: The trial met its primary safety endpoint with a major adverse event rate of only 5.1% at 12 months, providing robust safety support for the clinical application of FARAPULSE™ technology and boosting physician confidence in its use.
- WATCHMAN™ Device Performance: The WATCHMAN FLX™ LAAC device achieved a 100% acute success rate in the ALIGN-AF study, with 90.6% of patients achieving complete left atrial appendage closure within an average of 66 days, demonstrating its efficacy and safety in atrial fibrillation patients, which may enhance its market acceptance.
- Long-term Efficacy Data: Five-year follow-up data from the ASAP-TOO trial revealed a lower ischemic stroke rate of 7.8% in patients using the WATCHMAN device compared to 11.4% in the control group, providing a new treatment option for atrial fibrillation patients and potentially driving further growth for the company in the cardiac field.
See More
Boston Scientific Unveils Positive Data for Cardiac Therapies
- Clinical Trial Results: The FARAPULSE™ PFA Platform met all safety and effectiveness endpoints in the AVANT GUARD trial, demonstrating significant superiority over anti-arrhythmic drugs in treating patients with persistent atrial fibrillation, potentially expanding its use in high-risk populations.
- New Device Evaluation: The ongoing ELEVATE-PF feasibility trial is assessing the safety and effectiveness of the FARAFLEX™ PFA Catheter in patients with complex arrhythmias, with preliminary results expected to inform future treatment optimization strategies.
- Combined Treatment Benefits: The ALIGN-AF study indicates that the combination of the FARAWAVE PFA Catheter and WATCHMAN FLX™ LAAC Device was safely performed in 122 patients without compromising acute procedural success, highlighting the clinical potential of this combined therapeutic approach.
- Long-term Efficacy Analysis: Five-year follow-up data from the ASAP-TOO trial shows that the WATCHMAN LAAC device effectively reduces the risk of ischemic stroke in patients unsuitable for anticoagulation, providing new evidence of its clinical value despite early trial termination due to slow enrollment.
See More
Boston Scientific Unveils Positive Data for Cardiac Therapies
- Clinical Trial Results: The FARAPULSE™ Pulsed Field Ablation platform demonstrated a primary effectiveness rate of 56.0% in the AVANT GUARD trial, significantly surpassing the 30.1% rate of anti-arrhythmic drugs, indicating its potential in treating patients with persistent atrial fibrillation and possibly enhancing the company's leadership in the cardiac treatment market.
- Safety Metrics Achieved: The trial met its primary safety endpoint with a major adverse event rate of only 5.1% at 12 months, providing robust safety support for the clinical application of the FARAPULSE™ technology and boosting physician confidence in its use.
- Device Efficacy: The ELEVATE-PF feasibility trial showed that the FARAFLEX™ PFA catheter increased pulmonary vein isolation durability from 80.4% to 96.4%, demonstrating its effectiveness in treating complex arrhythmias and potentially laying the groundwork for future market adoption.
- Success of Combined Therapies: The ALIGN-AF study indicated a 100% procedural success rate for the combined use of the FARAWAVE PFA catheter and the WATCHMAN FLX™ LAAC device, suggesting that their joint application is both safe and effective in clinical settings, which may drive the expansion of the company's product offerings in cardiac care.
See More
Boston Scientific Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Boston Scientific Corporation has been hit with a class action lawsuit for alleged violations of federal securities laws, targeting investors who purchased its securities between July 23, 2025, and February 3, 2026, highlighting significant deficiencies in the company's financial transparency.
- False Statements Allegations: The complaint alleges that the company made materially false and misleading statements during the relevant period, failing to disclose that the growth rate of its U.S. electrophysiology segment was unsustainable, severely undermining investor confidence in the company's future prospects.
- Market Impact: The management's failure to timely disclose adverse trends affecting the electrophysiology segment, including declining procedure volumes and increasing competitive pressures, could lead to substantial financial losses for investors, further impacting the company's stock price and market reputation.
- Investor Action: Investors are encouraged to apply to be lead plaintiffs by May 4, 2026, to share in any potential recovery from the lawsuit, underscoring the importance of legal action in protecting investor rights.
See More
BOSTON SCIENTIFIC CORP.: BARCLAYS LOWERS TARGET PRICE FROM $100 TO $96
Barclays Adjusts Target Price: Barclays has reduced its target price for a specific stock from $100 to $96.
Market Implications: This adjustment may reflect changing market conditions or company performance expectations.
See More
Boston Scientific Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, to apply as lead plaintiffs by May 4, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made positive statements while concealing the unsustainable growth of its U.S. Electrophysiology segment, leading to investor losses when the company missed net income expectations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, ranked No. 1 by ISS in 2017, highlighting its expertise and success in this field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven track record to ensure effective representation in the class action, avoiding firms that merely act as intermediaries.
See More
Boston Scientific Releases New Data on Cardiac Therapies
- Clinical Trial Results: The FARAPULSE™ PFA platform demonstrated a primary effectiveness rate of 56.0% in the AVANT GUARD trial, significantly surpassing the 30.1% rate of anti-arrhythmic drugs, indicating its potential in treating patients with persistent atrial fibrillation and potentially enhancing the company's leadership in the cardiac treatment market.
- Safety Validation: The trial met its primary safety endpoint with a major adverse event rate of only 5.1% at 12 months, providing robust safety support for the clinical application of FARAPULSE™ technology and boosting physician confidence in its use.
- WATCHMAN™ Device Performance: The WATCHMAN FLX™ LAAC device achieved a 100% acute success rate in the ALIGN-AF study, with 90.6% of patients achieving complete left atrial appendage closure within an average of 66 days, demonstrating its efficacy and safety in atrial fibrillation patients, which may enhance its market acceptance.
- Long-term Efficacy Data: Five-year follow-up data from the ASAP-TOO trial revealed a lower ischemic stroke rate of 7.8% in patients using the WATCHMAN device compared to 11.4% in the control group, providing a new treatment option for atrial fibrillation patients and potentially driving further growth for the company in the cardiac field.
See More
Boston Scientific Unveils Positive Data for Cardiac Therapies
- Clinical Trial Results: The FARAPULSE™ PFA Platform met all safety and effectiveness endpoints in the AVANT GUARD trial, demonstrating significant superiority over anti-arrhythmic drugs in treating patients with persistent atrial fibrillation, potentially expanding its use in high-risk populations.
- New Device Evaluation: The ongoing ELEVATE-PF feasibility trial is assessing the safety and effectiveness of the FARAFLEX™ PFA Catheter in patients with complex arrhythmias, with preliminary results expected to inform future treatment optimization strategies.
- Combined Treatment Benefits: The ALIGN-AF study indicates that the combination of the FARAWAVE PFA Catheter and WATCHMAN FLX™ LAAC Device was safely performed in 122 patients without compromising acute procedural success, highlighting the clinical potential of this combined therapeutic approach.
- Long-term Efficacy Analysis: Five-year follow-up data from the ASAP-TOO trial shows that the WATCHMAN LAAC device effectively reduces the risk of ischemic stroke in patients unsuitable for anticoagulation, providing new evidence of its clinical value despite early trial termination due to slow enrollment.
See More
Boston Scientific Unveils Positive Data for Cardiac Therapies
- Clinical Trial Results: The FARAPULSE™ Pulsed Field Ablation platform demonstrated a primary effectiveness rate of 56.0% in the AVANT GUARD trial, significantly surpassing the 30.1% rate of anti-arrhythmic drugs, indicating its potential in treating patients with persistent atrial fibrillation and possibly enhancing the company's leadership in the cardiac treatment market.
- Safety Metrics Achieved: The trial met its primary safety endpoint with a major adverse event rate of only 5.1% at 12 months, providing robust safety support for the clinical application of the FARAPULSE™ technology and boosting physician confidence in its use.
- Device Efficacy: The ELEVATE-PF feasibility trial showed that the FARAFLEX™ PFA catheter increased pulmonary vein isolation durability from 80.4% to 96.4%, demonstrating its effectiveness in treating complex arrhythmias and potentially laying the groundwork for future market adoption.
- Success of Combined Therapies: The ALIGN-AF study indicated a 100% procedural success rate for the combined use of the FARAWAVE PFA catheter and the WATCHMAN FLX™ LAAC device, suggesting that their joint application is both safe and effective in clinical settings, which may drive the expansion of the company's product offerings in cardiac care.
See More
Boston Scientific Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Boston Scientific Corporation has been hit with a class action lawsuit for alleged violations of federal securities laws, targeting investors who purchased its securities between July 23, 2025, and February 3, 2026, highlighting significant deficiencies in the company's financial transparency.
- False Statements Allegations: The complaint alleges that the company made materially false and misleading statements during the relevant period, failing to disclose that the growth rate of its U.S. electrophysiology segment was unsustainable, severely undermining investor confidence in the company's future prospects.
- Market Impact: The management's failure to timely disclose adverse trends affecting the electrophysiology segment, including declining procedure volumes and increasing competitive pressures, could lead to substantial financial losses for investors, further impacting the company's stock price and market reputation.
- Investor Action: Investors are encouraged to apply to be lead plaintiffs by May 4, 2026, to share in any potential recovery from the lawsuit, underscoring the importance of legal action in protecting investor rights.
See More
BOSTON SCIENTIFIC CORP.: BARCLAYS LOWERS TARGET PRICE FROM $100 TO $96
Barclays Adjusts Target Price: Barclays has reduced its target price for a specific stock from $100 to $96.
Market Implications: This adjustment may reflect changing market conditions or company performance expectations.
See More
Boston Scientific Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, to apply as lead plaintiffs by May 4, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made positive statements while concealing the unsustainable growth of its U.S. Electrophysiology segment, leading to investor losses when the company missed net income expectations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, ranked No. 1 by ISS in 2017, highlighting its expertise and success in this field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven track record to ensure effective representation in the class action, avoiding firms that merely act as intermediaries.
See More
